|1.||Moore, Philip K: 7 articles (10/2015 - 05/2008)|
|2.||Li, Ling: 5 articles (08/2013 - 05/2008)|
|3.||Whiteman, Matthew: 4 articles (01/2015 - 05/2008)|
|4.||Tan, Choon-Hong: 4 articles (08/2013 - 05/2008)|
|5.||Meng, Guoliang: 3 articles (05/2015 - 08/2013)|
|6.||Ji, Yong: 3 articles (05/2015 - 08/2013)|
|7.||Xie, Liping: 3 articles (05/2015 - 08/2013)|
|8.||Peh, Meng Teng: 2 articles (10/2015 - 08/2013)|
|9.||Xiao, Yujiao: 2 articles (05/2015 - 01/2015)|
|10.||Wood, Mark E: 2 articles (01/2015 - 03/2013)|
07/01/2009 - "The possibility that GYY4137 and other slow-releasing H(2)S donors exert anti-inflammatory activity in other models of inflammation and in humans warrants further study."
03/01/2013 - "Thus, although GYY4137 consistently reduced the generation of pro-inflammatory mediators from human joint cells in vitro, its effect on acute joint inflammation in vivo depended on the timing of administration."
07/01/2014 - "To test if it might offer therapeutic value in the treatment of osteoarthritis (OA) we evaluated the effects of two exogenous sources of H2S, NaSH and GYY4137, on inflammation and catabolic markers that characterize OA. "
03/01/2013 - "We have also examined the effect of GYY4137 in a complete Freund's adjuvant (CFA) model of acute joint inflammation in the mouse. "
03/01/2013 - "The complex effects of the slow-releasing hydrogen sulfide donor GYY4137 in a model of acute joint inflammation and in human cartilage cells."
|2.||Atherosclerotic Plaque (Atheroma)
08/01/2013 - "In vivo, GYY4137 decreased aortic atherosclerotic plaque formation and partially restored aortic endothelium-dependent relaxation in apoE(-/-) mice. "
08/01/2013 - "In vivo, GYY4137 decreased vascular inflammation and oxidative stress, improved endothelial function and reduced atherosclerotic plaque formation in apoE(-/-) mice."
03/15/2014 - "Growing evidence suggests that atherosclerosis is associated with vascular CSE/H2S deficiency and that H2S supplementation by exogenous H2S donors (such as NaHS and GYY4137) attenuates, and H2S synthesis suppression by inhibitors (such as D, L-propargylglycine) aggravates the development of atherosclerotic plaques. "
01/01/2015 - "These results indicate that GYY4137 improves myocardial fibrosis perhaps by a mechanism involving inhibition of oxidative stress, blockade of the TGF-β1/Smad2 signaling pathway, and decrease in α-SMA expression in cardiac fibroblasts. "
01/01/2015 - "We investigated the effect of GYY4137, a slow-releasing H2S donor, on myocardial fibrosis. "
01/01/2015 - "Hydrogen Sulfide Donor GYY4137 Protects against Myocardial Fibrosis."
01/01/2015 - "GYY4137 decreased systolic blood pressure and inhibited myocardial fibrosis in SHR as evidenced by improved cardiac collagen volume fraction (CVF) in the left ventricle (LV), ratio of perivascular collagen area (PVCA) to lumen area (LA) in perivascular regions, reduced hydroxyproline concentration, collagen I and III mRNA expression, and cross-linked collagen. "
01/01/2015 - "We tested the effects of GYY4137 (a slow-releasing H2S donor), NaHS (an exogenous H2S donor) and NADPH oxidase 4 (NOX4) siRNA on reactive oxygen species (ROS) production, MMP-2,9, cystathionine-γ-lyase (CSE), NOX4, and extracellular signal-regulated kinase 1/2 (ERK1/2) to reveal the effects of H2S on the cardiac fibrosis of diabetic cardiomyopathy. "
|4.||Right Ventricular Hypertrophy
01/01/2011 - "We conclude that GYY4137 exhibits anti-cancer activity by releasing H₂S over a period of days. "
01/01/2011 - "Mice xenograft studies using HL-60 and MV4-11 cells showed that GYY4137 (100-300 mg/kg/day for 14 days) significantly reduced tumor growth. "
04/01/2014 - "In vivo, GYY4137 significantly inhibited tumor growth in the subcutaneous HepG2 xenograft model by inhibiting STAT3 activation and its target gene expression. "
04/01/2014 - "GYY4137, a hydrogen sulfide (H2S) donor, exhibits anticancer activity by a combination of cell cycle arrest and promoting apoptosis, and inhibits tumor growth, however, the precise mechanisms involved remain unclear. "
01/01/2011 - "The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo."
|1.||Messenger RNA (mRNA)
|2.||Hydroxyproline (4 Hydroxyproline)
|4.||Apolipoproteins E (ApoE)
|6.||Hydrogen Sulfide (Sulfide, Hydrogen)
|7.||sodium bisulfide (NaHS)
|8.||Reactive Oxygen Species (Oxygen Radicals)
|10.||Mitogen-Activated Protein Kinase 3
|1.||Heterologous Transplantation (Xenotransplantation)